Filing Flows › Cytek Biosciences (CTKB) › Q3 2026
Cytek Biosciences (CTKB) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 4, 2026
Cytek Biosciences (CTKB) reported revenue of $53.2M for the third quarter 2026 (Q3 2026), +2% from a year earlier and +11% from the quarter before. Operating margin was -15.8%, net loss $6.1M (11.5% of revenue).
Cytek Biosciences, Q3 2026: revenue $53.2M (+2% year over year), operating margin -15.8%, net loss $6.1M, operating cash flow −$4.5M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $53.2M | +11% | +2% |
| Operating profit | −$8.4M | — | — |
| Net earnings | −$6.1M | — | — |
| Operating cash flow | −$4.5M | -426% | — |
What changed
Revenue was $53.2M in Q3 2026, up 2% year over year and up 11% from the previous quarter. Product was the largest line at 70% of revenue. Service added $1.9M year over year (up 13%), 202% of the total change. Product declined 3%.
Gross margin was 58.6%, up 5.9 points from Q3 2025. Operating costs exceeded revenue by $8.4M, an operating margin of -15.8%. Operating expenses grew 8% against revenue growth of 2%. The fastest-growing cost line was General & admin (+14%). The quarter ended with a net loss of $6.1M, narrower than the previous quarter's $12.2M loss. Non-operating items added $1.5M, -22% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$4.5M. Non-cash charges added back $2.1M of depreciation and amortization and $4.9M of share-based compensation. Working capital and other items used $5.3M. Capital expenditures of $1.5M exceeded it, leaving free cash flow of −$6.0M.
Questions
What was Cytek Biosciences' revenue in the third quarter 2026?
Cytek Biosciences (CTKB) reported revenue of $53.2M for the third quarter 2026 (Q3 2026), +2% from a year earlier and +11% from the quarter before.
Was Cytek Biosciences profitable in the third quarter 2026?
Operating loss was $8.4M (-15.8% of revenue) and net loss $6.1M.
Source: Cytek Biosciences 10-Q on SEC EDGAR.